Cooley advised Sucampo Pharmaceuticals on its acquisition of rare disease biotech firm Vtesse for $200 million in cash and stock in upfront payments and contingent payments…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
